Join us for an Investor R&D Day webcast hosted by IDEAYA Biosciences, discussing scientific insights and future clinical development plans across its broad pipeline of synthetic lethality therapeutics, an emerging area of precision medicine oncology.

Agenda Topics

• The Synthetic Lethality Paradigm
• Overview of Current State of Synthetic Lethality Therapy Opportunity in Oncology
• IDEAYA Vision, Strategy and Pipeline
• Darovasertib Clinical Evaluation in Neoadjuvant Uveal Melanoma
• Clinical Development Plan and Potential Patient Impact
• Mechanistic Advances Support Combination Approaches to Treat MTAP Deleted Tumors
• Dual Synthetic Lethal Strategy for MAT2A Clinical Combination Therapies
• Selective Essentiality in DNA Damage Repair
• Introduction – IDEAYA’s DDR Synthetic Lethality Pipeline
• Targeting Replication Stress is an Emerging Synthetic Lethality Paradigm
• Novel Approach to HRD: IDE161 PARG inhibitor Preclinical Activity and Clinical Development Plan
• Werner Helicase is a Cornerstone Synthetic Lethality Target for MSI-High Cancers
• Targeting Pol Theta to Enhance and Maintain Control of HRD Tumors

Key Opinion Leader Presenters

• Frank McCormick, Ph.D., FRS, D.Sc (Hon), Professor, Helen Diller Family Comprehensive Cancer Center and Department of Cellular and Molecular Pharmacology, and Chair, David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, University of California San Francisco (UCSF)
• Carol Shields, M.D., Chief, Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University
• Karlene Cimprich, Ph.D., Professor, Chemical and Systems Biology and (by courtesy) Biochemistry, Member, Stanford Cancer Institute, Stanford University
• Timothy Yap, M.D., Associate Professor, Department for Investigational Cancer Therapeutics and Department of Thoracic/Head and Neck Medical Oncology, Medical Director, Institute for Applied Cancer Science, Associate Director of Translational Research, Institute for Personalized Cancer Therapy, M.D. Anderson Cancer Center
• Matthew Garnett, Ph.D., Leader, Translational Cancer Genomics, Wellcome Sanger Institute
• Benjamin Schwartz, Ph.D., Vice President, Head of Oncology Synthetic Lethality Research Unit, GSK

The event will conclude with closing remarks, followed by a live analyst Q&A session

CONTACT US

Investor Inquiries: investor@ideayabio.com